Lastet 50 Capsule contains Etoposide 50 mg, a chemotherapeutic agent used primarily in the treatment of various malignancies including small cell lung cancer, testicular cancer, lymphomas, and certain types of leukemia. Etoposide acts as a topoisomerase II inhibitor, interfering with DNA synthesis and inducing DNA strand breaks, which ultimately leads to apoptosis of rapidly dividing cancer cells. The capsule formulation allows for oral administration, offering convenience and improved patient compliance compared to intravenous routes. Lastet 50 should be used under strict medical supervision, with dosing tailored according to the specific cancer type, stage, and patient’s overall health status. Common adverse effects include myelosuppression, nausea, vomiting, alopecia, and mucositis; therefore, regular monitoring of blood counts and clinical status is essential during therapy. Patients should be advised on potential risks including immunosuppression and secondary malignancies. Lastet 50 is contraindicated in patients with hypersensitivity to Etoposide or any capsule excipients and should be used cautiously in those with hepatic or renal impairment. This medication is a critical component of combination chemotherapy regimens and should be administered as part of a comprehensive cancer treatment plan under the guidance of an oncologist.